Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH. Dijkgraaf EM, et al. Among authors: reyners ak. Oncotarget. 2015 Oct 13;6(31):32228-43. doi: 10.18632/oncotarget.4772. Oncotarget. 2015. PMID: 26334096 Free PMC article. Clinical Trial.
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, Welters MJ, van der Burg SH, Kroep JR. Dijkgraaf EM, et al. Among authors: reyners ak. Ann Oncol. 2015 Oct;26(10):2141-9. doi: 10.1093/annonc/mdv309. Epub 2015 Jul 27. Ann Oncol. 2015. PMID: 26216383 Free article. Clinical Trial.
Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification.
Eggink FA, Mom CH, Bouwman K, Boll D, Becker JH, Creutzberg CL, Niemeijer GC, van Driel WJ, Reyners AK, van der Zee AG, Bremer GL, Ezendam NP, Kruitwagen RF, Pijnenborg JM, Hollema H, Nijman HW, van der Aa MA. Eggink FA, et al. Among authors: reyners ak. Eur J Cancer. 2017 Jun;78:82-90. doi: 10.1016/j.ejca.2017.03.010. Epub 2017 Apr 14. Eur J Cancer. 2017. PMID: 28415003
Corrigendum to "Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification" [Eur J Cancer 78 (2017) 82-90].
Eggink FA, Mom CH, Bouwman K, Boll D, Becker JH, Creutzberg CL, Niemeijer GC, van Driel WJ, Reyners AK, van der Zee AG, Bremer GL, Ezendam NP, Kruitwagen RF, Pijnenborg JM, Hollema H, Nijman HW, van der Aa MA. Eggink FA, et al. Among authors: reyners ak. Eur J Cancer. 2017 Oct;84:370. doi: 10.1016/j.ejca.2017.08.003. Epub 2017 Aug 23. Eur J Cancer. 2017. PMID: 28844347 No abstract available.
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
Reyners AKL, de Munck L, Erdkamp FLG, Smit WM, Hoekman K, Lalisang RI, de Graaf H, Wymenga ANM, Polee M, Hollema H, van Vugt MATM, Schaapveld M, Willemse PHB; DoCaCel Study Group. Reyners AKL, et al. Ann Oncol. 2012 Nov;23(11):2896-2902. doi: 10.1093/annonc/mds107. Epub 2012 Jun 11. Ann Oncol. 2012. PMID: 22689176 Free article. Clinical Trial.
164 results